Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences Stock Forecast

Stock Price Forecast

The 18 analysts that cover Neurocrine Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $172.06, which forecasts a 15.16% increase in the stock price over the next year. The lowest target is $115 and the highest is $203.

Price Target: $172.06 (+15.16%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$115	$172.06	$179	$203
Change	-23.03%	+15.16%	+19.80%	+35.87%

Analyst Ratings

The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jun '25	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25
Strong Buy	7	10	10	9	10	10
Buy	11	10	8	7	7	7
Hold	2	2	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	22	19	17	18	18

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anupam Rama JP Morgan	JP Morgan	Buy Maintains $171 → $179	Buy	Maintains	$171 → $179	+19.80%	Nov 3, 2025
Danielle Brill Truist Securities	Truist Securities	Strong Buy Reiterates $165 → $172	Strong Buy	Reiterates	$165 → $172	+15.12%	Oct 30, 2025
Sumant Kulkarni Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $160 → $164	Strong Buy	Maintains	$160 → $164	+9.77%	Oct 29, 2025
Yigal Nochomovitz Citigroup	Citigroup	Strong Buy Maintains $175 → $203	Strong Buy	Maintains	$175 → $203	+35.87%	Oct 29, 2025
Paul Matteis Stifel	Stifel	Strong Buy Maintains $174 → $183	Strong Buy	Maintains	$174 → $183	+22.48%	Oct 29, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.91B

Increased by 23.68%

from 2.36B

Revenue Next Year

3.44B

Increased by 18.02%

from 2.91B

EPS This Year

5.05

Increased by 53.46%

from 3.29

EPS Next Year

6.90

Increased by 36.63%

from 5.05

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.05B	1.13B	1.49B	1.89B	2.36B	2.91B	3.44B
Revenue Growth	32.71%	8.38%	31.34%	26.76%	24.81%	23.68%	18.02%
EPS	4.16	0.92	1.56	2.47	3.29	5.05	6.90
EPS Growth	966.67%	-77.89%	69.57%	58.33%	33.20%	53.46%	36.63%
Forward PE	-	-	-	-	-	29.59	21.66
No. Analysts	-	-	-	-	-	30	29

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	3.0B	3.8B
Avg	2.9B	3.4B
Low	2.7B	3.0B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	29.2%	31.5%
Avg	23.7%	18.0%
Low	15.6%	4.5%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	5.82	9.45
Avg	5.05	6.90
Low	4.20	3.55

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	76.8%	87.2%
Avg	53.5%	36.6%
Low	27.8%	-29.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.